HANNOVER, Germany, October 27 /PRNewswire/ -- BioVisioN AG, based in Hannover, Germany, has reached an important milestone in its collaboration with Danish pharmaceutical company Novo Nordisk A/S. Financial details were not disclosed. Under the terms of the collaboration agreement, BioVisioN analysed samples provided by Novo Nordisk using its proprietary Peptidomics(R) technologies. In the course of the project new bioactive molecules were identified and validated successfully.
"We are quite delighted that after the intense working phase the outcome of the study was positive for the purposes of our customer.", says BioVisioN's Chief Business Officer Dr. Rainer Voegeli. "Again our unique approach to biomarker and lead discovery was successful and time efficient."
BioVisioN AG specialises in the identification of disease-relevant peptides and proteins using Peptidomics(R) in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organisation.
Novo Nordisk is a focused healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. For more information, visit http://www.novonordisk.com/.
CONTACT: Contact: Dr. Rainer Voegeli, Head of Business Development,BioVisioN AG, Feodor-Lynen-Str. 5, 30625 Hannover , Fon:+49(0)511-538-896-0, Fax: +49(0)511-538-896-66,firstname.lastname@example.org